These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24336963)

  • 1. In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach.
    George Priya Doss C; Rajith B; Chakraboty C; Balaji V; Magesh R; Gowthami B; Menon S; Swati M; Trivedi M; Paul J; Vasan R; Das M
    Mol Biosyst; 2014 Mar; 10(3):421-36. PubMed ID: 24336963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.
    Dixit A; Torkamani A; Schork NJ; Verkhivker G
    Biophys J; 2009 Feb; 96(3):858-74. PubMed ID: 19186126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defects in the calcium-binding region drastically affect the cadherin-like domains of RET tyrosine kinase.
    Gao C; Grøtli M; Eriksson LA
    Phys Chem Chem Phys; 2016 Mar; 18(12):8673-81. PubMed ID: 26950000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
    Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
    Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
    Terzyan SS; Shen T; Liu X; Huang Q; Teng P; Zhou M; Hilberg F; Cai J; Mooers BHM; Wu J
    J Biol Chem; 2019 Jul; 294(27):10428-10437. PubMed ID: 31118272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular dynamics study of enhanced autophosphorylation by S904F mutation of the RET kinase domain.
    Chen YJ; Li PY; Yang CN
    J Struct Biol; 2021 Dec; 213(4):107799. PubMed ID: 34563653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.
    Moccia M; Liu Q; Guida T; Federico G; Brescia A; Zhao Z; Choi HG; Deng X; Tan L; Wang J; Billaud M; Gray NS; Carlomagno F; Santoro M
    PLoS One; 2015; 10(6):e0128364. PubMed ID: 26046350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B.
    Cranston AN; Carniti C; Oakhill K; Radzio-Andzelm E; Stone EA; McCallion AS; Hodgson S; Clarke S; Mondellini P; Leyland J; Pierotti MA; Whittaker J; Taylor SS; Bongarzone I; Ponder BA
    Cancer Res; 2006 Oct; 66(20):10179-87. PubMed ID: 17047083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold.
    Brandt W; Mologni L; Preu L; Lemcke T; Gambacorti-Passerini C; Kunick C
    Eur J Med Chem; 2010 Jul; 45(7):2919-27. PubMed ID: 20409618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.
    Gao C; Grøtli M; Eriksson LA
    J Mol Model; 2015 Jul; 21(7):167. PubMed ID: 26044359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B.
    Gujral TS; Singh VK; Jia Z; Mulligan LM
    Cancer Res; 2006 Nov; 66(22):10741-9. PubMed ID: 17108110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.
    Cao S; Tan C; Fei A; Hu G; Fu M; Lv J
    J Mol Model; 2022 Dec; 29(1):24. PubMed ID: 36576611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of V54M mutation in giant muscle protein titin: a computational screening and molecular dynamics approach.
    Thirumal Kumar D; George Priya Doss C; Sneha P; Tayubi IA; Siva R; Chakraborty C; Magesh R
    J Biomol Struct Dyn; 2017 Apr; 35(5):917-928. PubMed ID: 27125723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple functional effects of RET kinase domain sequence variants in Hirschsprung disease.
    Hyndman BD; Gujral TS; Krieger JR; Cockburn JG; Mulligan LM
    Hum Mutat; 2013 Jan; 34(1):132-42. PubMed ID: 22837065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046.
    Repetto M; Crimini E; Ascione L; Boscolo Bielo L; Belli C; Curigliano G
    Invest New Drugs; 2022 Oct; 40(5):1133-1136. PubMed ID: 35612671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the impact of deleterious mutations in the protein kinase domain of FGFR2 in the context of function, structure, and pathogenesis--a bioinformatics approach.
    C GP; Rajith B; Chakraborty C
    Appl Biochem Biotechnol; 2013 Aug; 170(8):1853-70. PubMed ID: 23754559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2.
    Gujral TS; Mulligan LM
    Ann N Y Acad Sci; 2006 Aug; 1073():234-40. PubMed ID: 17102091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
    Yoon H; Shin I; Nam Y; Kim ND; Lee KB; Sim T
    Eur J Med Chem; 2017 Jan; 125():1145-1155. PubMed ID: 27814560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach.
    Kumar DT; Doss CG
    Adv Protein Chem Struct Biol; 2016; 102():267-97. PubMed ID: 26827608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.